In 165 patients with persistent chemotherapy-induced thrombocytopenia on oxaliplatin-based chemotherapy for GI cancers, romiplostim vs placebo meant more had no CIT-related dose modification in cycles 2-3 (84% vs 36%); grade ≥3 AEs 37% vs 22%, thromboembolism 2% vs 0%.
RCTn = 165
Al-Samkari et al. Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia